Platform Candidate
Ovarian Cancer
Key Facts
About FLAG Therapeutics
FLAG Therapeutics is a private, preclinical-stage biotech company developing small molecule oncology drugs for high-unmet-need cancers. Its strategy centers on three proprietary platforms that generate dual- or multi-action compounds, with an initial focus on pediatric DIPG and adult GBM. The company recently secured over $500,000 in equity and impact funding from a mix of venture and mission-driven investors. With lead program FLAG-003 on track for a Phase 1/2 trial in 2026, FLAG aims to address some of the most aggressive and lethal cancers.
View full company profileAbout FLAG Therapeutics
FLAG Therapeutics is a private, preclinical-stage biotech company developing small molecule oncology drugs for high-unmet-need cancers. Its strategy centers on three proprietary platforms that generate dual- or multi-action compounds, with an initial focus on pediatric DIPG and adult GBM. The company recently secured over $500,000 in equity and impact funding from a mix of venture and mission-driven investors. With lead program FLAG-003 on track for a Phase 1/2 trial in 2026, FLAG aims to address some of the most aggressive and lethal cancers.
View full company profileAbout FLAG Therapeutics
FLAG Therapeutics is a private, preclinical-stage biotech company developing small molecule oncology drugs for high-unmet-need cancers. Its strategy centers on three proprietary platforms that generate dual- or multi-action compounds, with an initial focus on pediatric DIPG and adult GBM. The company recently secured over $500,000 in equity and impact funding from a mix of venture and mission-driven investors. With lead program FLAG-003 on track for a Phase 1/2 trial in 2026, FLAG aims to address some of the most aggressive and lethal cancers.
View full company profileTherapeutic Areas
Other Ovarian Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| EXO‑Ovarian Cancer Test | INOVIQ | Phase 2/3 |
| CAR‑iNK‑OvCa | Cartherics | Preclinical |
| MagSense™ FR Imaging Agent | Imagion Biosystems | Pre‑clinical |
| Yondelis (trabectedin) | PharmaMar | Approved |
| Measovir®-based candidate | Oncovita | Pre-clinical |
| NP-G2-044 + Chemotherapy Agents | Novita Pharmaceuticals | Phase 2a |
| Ivospemin (SBP-101) | Panbela Therapeutics | Phase 2 |
| Ovarian Cancer Early Detection Assay | GenEndeavor | Pre-clinical |
| INVAC-1 | Invectys | Phase 2 |
| Folate Receptor-Targeted PCC | Indi Molecular | Preclinical |
| Immunomodulator Platform | OmniCyte | Pre-clinical |
| High Internalization ADC | Lytica Therapeutics | Preclinical |